Back to Search
Start Over
Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report
- Source :
- International Journal of Infectious Diseases, Vol 97, Iss , Pp 215-218 (2020)
- Publication Year :
- 2020
- Publisher :
- Elsevier, 2020.
-
Abstract
- We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy, of a severe case of novel coronavirus disease 2019 (COVID-19). We describe the diagnosis, clinical course, and management of the case, including the respiratory failure at presentation, the progression to a scenario characterized by profound inflammatory dysregulation similar to that observed during macrophage activation syndrome, and the clinical improvement after treatment with the IL-1 receptor antagonist anakinra. This case highlights the high tolerability and the interesting immunomodulatory profile of the IL-1 receptor antagonist anakinra in the setting of severe COVID-19 associated with remdesivir therapy. Further studies are needed to confirm the safety and efficacy of this combination strategy in the treatment of this emerging infection.
Details
- Language :
- English
- ISSN :
- 12019712
- Volume :
- 97
- Issue :
- 215-218
- Database :
- Directory of Open Access Journals
- Journal :
- International Journal of Infectious Diseases
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.9c02e8951a1342d5b79ed9cda0b4d0da
- Document Type :
- article
- Full Text :
- https://doi.org/10.1016/j.ijid.2020.05.050